PECAM1 and neoplasm: As shown in Fig. 1f, tumor xenograft sections from CPTH6-treated tumors showed a reduced CD31-positivity when compared to control xenografts, suggesting that the anti-tumor activity of CPTH6 may rely also on its ability to affect tumor vascularization.